NewTimeSpace News: Nanjing Novlead Biotechnology Co., Ltd. filed with HKEX on 13 February 2026 with CCB International as sole sponsor, which lapsed after six months. The Company is the world's only enterprise covering a complete product line across NO therapeutic and diagnostic applications; core product iNOwill is the world's first electrochemical catalytic iNO therapy device (No. 1 by market share in China's iNO therapy market in 2024), with 5 approved products and 4 pipeline candidates.
NewTimeSpace News: On 12 August 2026, ZELGEN (688266.SH) filed its second listing application with HKEX, with CICC as sole sponsor. The Company has four marketed drugs and 10 candidates across 29 major clinical programmes, with ZG006 being the world's first DLL3/DLL3/CD3 trispecific antibody. Financially, the Company recorded aggregate net losses of approximately RMB 611 million in 2023-2025 and turned to a net profit of RMB 640 million in H1 2026 driven by the AbbVie upfront payment, while cautioning that the profitability may not be sustainable in the near term.
NewTimeSpace News: On 12 February 2026, Salubris (002294.SZ) submitted a listing application to the Hong Kong Stock Exchange, which lapsed after six months, with Goldman Sachs, Citi and CITIC Securities as sole sponsors; the company ranked second by revenue among China's cardiovascular innovative drug companies in 2024 and holds the second-largest CKM innovative drug pipeline among domestic companies, with innovative drug revenue share rising from 30.1% in 2023 to 37.7% in 2024 and further to 51.6% for the first nine months of 2025.
NewTimeSpace News: On 11 August 2026, Hangzhou CIEC Group Co., Ltd. re-submitted a listing application to the HKEX Main Board, with CICC as the sole sponsor; as a commodity industry service provider and trader, the Company ranks fifth in China by 2025 trade volume and sales revenue, second in steel exports and second in iron ore trade volume, with operations covering more than 80 countries and regions.
Newtimespace News: Beijing Kunlun Tech Co., Ltd. (300418.SZ) announced its plan to issue overseas-listed foreign capital shares (H-shares) and list on the Main Board of The Stock Exchange of Hong Kong Limited. The Company held the 2nd meeting of the 6th Board of Directors on 10 August 2026 and approved relevant proposals. The proposed offering is still subject to shareholders’ approval and regulatory consents from authorities including the China Securities Regulatory Commission and HKEX.
NewTimeSpace News: The listing application of Sieyuan Electric Co., Ltd. submitted to the HKEX on 11 February 2026 has lapsed, as it has been pending for six months, with CITIC SEC having served as the original sole sponsor. According to Frost & Sullivan, by 2024 revenue in China's power transmission, distribution and control equipment market, the Company ranked eighth among international enterprises, fifth among domestic enterprises and third among domestic private enterprises, with a market share of 3.5%. Its business has covered more than 100 countries and regions worldwide.
NewTimeSpace News: The listing application of Zhejiang Jingxin Pharmaceutical Co., Ltd. submitted to the HKEX on 11 February 2026 has lapsed, as it has been pending for six months, with CITIC SEC having served as the original sole sponsor. The Company is an innovation-driven pharmaceutical group strategically focused on two core therapeutic areas, central nervous system (CNS) diseases and cardiovascular and cerebrovascular diseases, with total revenue of approximately RMB 4.16 billion, net profit of approximately RMB 719 million and R&D investment of approximately RMB 384 million in 2024.
NewTimeSpace News: The listing application of PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd. submitted to the HKEX on 11 February 2026 has lapsed, as it has been pending for six months, with CISI FIN and ICBC International having served as the original joint sponsors. The Company is a clinical CRO headquartered in Hangzhou, posting a gross margin of 38.3% in 2024 (industry average of approximately 30%), a net margin of 19.8% (industry average of approximately 10%) and revenue per employee of RMB 0.85 million (industry average of approximately RMB 0.55 million), serving over 200 innovative pharmaceutical and biotechnology companies.
NewTimeSpace News: On 10 August 2026, EVER GLORY UNITED HOLDINGS LIMITED filed a listing application with the HKEX Main Board, with ICBC International as the sole sponsor; by 2025 revenue, the Company ranked second among local M&E engineering services providers in Singapore, with total revenue of SGD 121.6 million in 2025 and an order book of SGD 838.2 million as of 30 June 2026, which has since exceeded SGD 1 billion.
Newtimespace News: Vitalink Technology Co., Ltd. submitted its listing application to the Hong Kong Stock Exchange on 9 February 2026, which has lapsed upon the expiry of the six-month validity period. CICC and Deutsche Bank acted as the original joint sponsors. According to CIC Consulting, based on 2024 revenue, the Company is the world’s largest supplier of PVD interface enhancement solutions for consumer electronic metal components and ranks among the top three global vendors for glass component PVD interface enhancement solutions for consumer electronics. It has maintained decades-long partnerships with two of the world’s largest technology conglomerates.
Newtimespace News: Weiheng Intelligent Technology Co., Ltd. filed its HKEX listing application on 9 February 2026, which has lapsed upon the expiration of the six-month validity period. Huatai International and China Merchants Bank International acted as the original joint sponsors. According to Frost & Sullivan, for the nine months ended 30 September 2025, among 900 lithium-ion battery energy storage system integrators in China, the Company ranked eighth globally by commercial and industrial energy storage system shipment volume and third in overseas market shipments. Its business covers more than 50 countries and regions, with over 600 operational energy storage power stations.
Newtimespace News: Hangzhou Tangji Medical Technology Co., Ltd. filed its listing application with the Hong Kong Stock Exchange on 9 February 2026, which has lapsed upon the expiry of the six-month validity period. ICBC International and Caitong International acted as the original joint sponsors. Founded in 2016, the Company develops innovative medical device solutions for the treatment and full-cycle management of metabolic diseases, with its core product Gastric Bypass Stent System (GBS) commercially available. China’s obese population reached 224 million in 2024 and is projected to rise to 332 million by 2034.
Newtimespace News: Hangzhou CIEC Group Co., Ltd. submitted its listing application to the Hong Kong Stock Exchange on 9 February 2026, which has lapsed upon the expiry of the six-month validity period. China International Capital Corporation (CICC) acted as the original sole sponsor. According to Frost & Sullivan, measured by 2024 trading volume, the Company ranks fifth among China’s commodity industrial service providers and traders, the fourth-largest steel industrial service provider (second in steel exports), and the third-largest industrial service provider for iron ore and rubber products. Its business covers 14 countries and regions, with trading activities spanning more than 80 countries and regions worldwide.
Newtimespace News: Shenzhen Zeroth AI Technology Co., Ltd. submitted its Hong Kong stock exchange listing application on 10 February 2026, which has lapsed upon the expiration of the six-month validity period. Minyin Capital acted as the original sole sponsor. According to Frost & Sullivan, in terms of revenue for 2024, the Company is the fifth-largest supplier of enterprise AI agent solutions in China with a 3.0% market share. Its proprietary AI platform BlackZero underpins three vertical-specific solutions: Contract Assistant, Investment Assistant and Brand Assistant.
Newtimespace News: The listing application of ICS Corporate Services Group Inc., submitted to the Hong Kong Stock Exchange on 10 February 2026, has lapsed following the expiry of its six-month validity term. ABC International acted as the original sole sponsor. As a leading provider of professional overseas expansion services for enterprises, the Company ranked first among local service providers and second across all service vendors catering to Chinese firms going global by 2024 revenue, with a 10.5% market share. It is the first and only Chinese service provider holding full licenses covering BVI, Cayman and Hong Kong jurisdictions.
Newtimespace News: The listing application of Zhejiang Hexia Technologies Co., Ltd., submitted to HKEX GEM on 10 February 2026, has lapsed upon the expiry of the six-month validity period. Golden Link Capital acted as the original sole sponsor. Founded in 2017, the Company is a leading automotive test solution provider in Zhejiang Province, offering automotive testing, test system integration and auto component sales, with a client base covering numerous leading domestic and international automobile and component manufacturers.
